Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 6/20 | 0.42 |
| ▸ | PPP5C | P53041 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17342220 | 1.00 | GBA1 (0.42) | GBA1PPP5CTSHREPHX2ALDH1A1 | |
| SCHEMBL16769690 | 1.00 | GBA1 (0.42) | GBA1PPP5CTSHREPHX2ALDH1A1 | |
| SCHEMBL6852788 | 0.98 | GBA1 (0.41) | GBA1PPP5CTSHREPHX2ALDH1A1 | |
| SCHEMBL11943576 | 0.86 | GBA1 (0.42) | GBA1PPP5CTSHREPHX2ALDH1A1 | |
| SCHEMBL17384324 | 0.85 | GBA1 (0.38) | GBA1PPP5CTSHREPHX2ALDH1A1 | |
| SCHEMBL17384323 | 0.85 | GBA1 (0.38) | GBA1PPP5CTSHREPHX2ALDH1A1 | |
| SCHEMBL8970189 | 0.85 | GBA1 (0.38) | GBA1PPP5CTSHREPHX2ALDH1A1 | |
| SCHEMBL14153818 | 0.83 | GBA1 (0.44) | GBA1PPP5C | |
| SCHEMBL10076752 | 0.82 | CNR2 (0.36) | GBA1PPP5CTSHREPHX2 | |
| SCHEMBL10076832 | 0.80 | GBA1 (0.41) | GBA1PPP5CTSHREPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20230157999-A1 | PYRANO[4,3-B]INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-05-25 | — | — | US | disclosed |
| WO-2017139697-A9 | BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA | SYNLOGIC, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
| US-9809588-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170291895-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-10-12 | — | — | US | disclosed |
| US-20170158697-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2017-06-08 | — | — | US | disclosed |
| US-20160256448-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160257692-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9388161-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20160009704-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-14 | — | — | US | disclosed |
| US-20150232445-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
| WO-2015077866-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE INC. (CA) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015074064-A2 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BAIR KENNETH W (US) | 2015-05-21 | — | — | WO | disclosed |
| WO-2014124430-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2014-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160256448-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | GBA1 3488/4885PPP5C 2484/4885TSHR 1323/4885 |
| US-20230157999-A1 | PYRANO[4,3-B]INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | GBA1 1909/4885PPP5C 1046/4885TSHR 1834/4885 |
| US-20160009704-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | GBA1 12/4885PPP5C 2131/4885TSHR 3567/4885 |
| US-20150232445-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | GBA1 3488/4885PPP5C 2484/4885TSHR 1323/4885 |
| US-20170158697-A1 | Protein Kinase Inhibitors | TEC, LCK, SRC | GBA1 3753/4885PPP5C 211/4885TSHR 3176/4885 |
| US-20170291895-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | GBA1 12/4885PPP5C 2131/4885TSHR 3567/4885 |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | GBA1 319/4885PPP5C 1994/4885TSHR 2764/4885 |
| US-20160257692-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | GBA1 3488/4885PPP5C 2484/4885TSHR 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.